NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
M.D. Anderson Cancer Center
Pfizer
Children's Hospital Los Angeles
Grupo Español Multidisciplinar de Melanoma
Grupo Español Multidisciplinar de Melanoma